© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Tranilast began its journey in Japan during the late 1970s. Japanese researchers were trying to address the need for better anti-allergy medications. The earliest focus involved finding ways to block the release of chemical signals from mast cells, which contribute to allergic symptoms in asthma, atopic dermatitis, and allergic rhinitis. Tranilast grew out of these efforts as a small molecule that seemed to discourage the body from mounting an overactive inflammatory response. The Japanese regulatory authorities approved tranilast for clinical use, and its development moved into markets in several Asian countries. While it never made a big splash in the United States or Europe, its influence on anti-allergy research continues. Modern scientists have explored its broader anti-inflammatory and anti-fibrotic potential by looking at both original documents from the time and new work that builds on that legacy.
Tranilast stands as a synthetic molecule, best known as an anti-allergic and anti-fibrotic agent. It retails in powder form, either for direct use in compounding or for formulation into tablets and capsules. The pharmaceutical industry has often shaped it as a bulk powder of near-white color, and its main application has lingered in the realm of prescription drugs aimed at controlling chronic allergic and inflammatory conditions. Persistent research links it to future prospects as a wider anti-fibrotic option, a potential boon for organ scarring and chronic inflammatory diseases.
Tranilast appears as a slightly yellowish crystalline powder with a faint odor. Its solubility limits preparation options, as it dissolves sparingly in cold water but fares better in alcohols and DMSO. The compound has a melting point that settles around 175°C–180°C, making it easy to handle in standard laboratory settings. Chemically, its structure borrows characteristics from both anthranilic acid derivatives and cinnamic acid, so its molecule contains both amide and aromatic functional groups. That gives it specific reactivity in organic synthesis and helps explain its action at a molecular level.
Labeling for tranilast emphasizes purity, water content, identification, and heavy metal impurities. Official compendia—like Japanese and Chinese Pharmacopoeia—dictate that the product should contain at least 98% of the labeled active ingredient. Labels on pharmaceutical-grade lots give batch numbers, expiration dates, manufacturing origins, and the specific route of synthesis when available. Color-coding sometimes marks anti-allergy use to prevent mix-ups during compounding. Packaging usually comes in sealed, light-resistant containers to avoid photosensitive degradation. Laboratories test each batch for particle size and solubility to make sure it fits the requirements for solid oral dosage forms.
Most manufacturers rely on condensation reactions to build the tranilast molecule. Chemists often begin with anthranilic acid and couple it to trans-cinnamic acid derivatives. The amide bond becomes the key step, typically using activating agents such as carbodiimide or phosphorus oxychloride. Afterward, purification happens through recrystallization, followed by filtration, washing, and drying under vacuum to ensure a consistent, pharmaceutical-grade product. Since the 1980s, small-scale labs have experimented with milder and greener synthesis, including enzyme-assisted steps, but industrial production still favors established, scalable condensation chemistry.
Researchers have tinkered with tranilast’s core to stretch its uses in new directions. Substituting different groups on the aromatic rings can produce derivatives with altered bioactivity. Some teams have added bulkier substituents to improve water solubility or target novel anti-inflammatory pathways. Reactive centers let chemists build prodrugs or salts that improve absorption in the gut. Studies over the past decade show that chemical tweaks give analogs that modulate fibrosis in animal models better than the original molecule. Most of these modifications start with the parent structure and adjust the carboxyl or amino groups, then characterize the resulting chemical and biological properties. Large-scale commercial synthesis still focuses on the original structure for both regulatory approval and historical market confidence.
Tranilast appears under several names in different countries. The most recognized synonym worldwide remains N-(3′,4′-dimethoxycinnamoyl)anthranilic acid. In Japan and parts of Asia, products list it under the brand name Rizaben or Tranilastum. In research literature, it may appear simply by its structure descriptor or its registry number (CAS 53902-12-8). Some sources still refer to it as “3'-4'-dimethoxycinnamoyl anthranilate” for clarity when distinguishing it from related molecules.
Handling tranilast in manufacturing or pharmaceutical compounding environments requires guidelines typical for synthetic organic powders. Staff use gloves, goggles, and dust masks to avoid inhaling or touching powders. Storage guidelines state that it should be kept away from sunlight and moisture. Batch control and traceability standards come straight from good manufacturing practice (GMP), including mandatory retention samples and regular equipment cleaning. Pharmacies store tranilast in areas reserved for prescription-only drugs to keep accidental use off the table. Facilities favor local exhaust ventilation during weighing and transfer, which protects staff and helps preserve product stability. Training for anyone who works with the product covers spill response and first aid, nudging operations away from accidental skin or eye contact as much as possible.
Doctors in Japan, South Korea, and China use tranilast to treat asthma, atopic dermatitis, allergic conjunctivitis, and keloid formation. It finds a stronghold where chronic inflammation and abnormal tissue repair give trouble, such as with hypertrophic scars. Medical teams have even deployed it for rare diseases that cause organ fibrosis, based on experimental protocols. Some researchers in Europe and the US have looked at it off-label for idiopathic pulmonary fibrosis, though access outside Asia often comes through special approval or clinical trial enrollment. Tranilast can be used alone or with steroids and other anti-allergy drugs, as part of stepwise therapy guided by patient response.
Research continues at a brisk pace, focusing on the potential of tranilast to slow or reverse tissue scarring and fibrosis. Teams conduct cell and animal studies looking at how tranilast might interfere with TGF-beta signaling, a driving force behind abnormal wound healing and fibrosis. Recent clinical trials are trying to pinpoint whether patients with heart failure, scleroderma, or diabetic kidney disease could benefit. Pharmaceutical chemists stay busy building analogs with better absorption and fewer side effects. Collaboration between universities and biotech firms has brought new eyes to the puzzle of anti-fibrotic therapy, especially as conditions like nonalcoholic steatohepatitis become more common. Evidence builds through the decades, each study stacking up experience rather than floating on speculation.
The bulk of safety studies on tranilast come from human and animal trials over the past 40 years. Typical doses carry a low risk of severe toxicity, though some patients have seen mild liver enzyme elevations, rash, or rare kidney inflammation with prolonged high doses. Animal studies looked for mutagenic or carcinogenic potential, and most have cleared tranilast of major concern. Long-term clinical use in Asian populations supports its safety for most, but regular monitoring—especially liver and kidney function—remains part of routine care for long-term users. Researchers have paid attention to rare hypersensitivity and adverse cardiac effects, but these stories appear infrequently in the literature. Clear, reproducible reporting keeps risks transparent and helps make room for new safety data as clinical applications expand.
Tranilast’s place in tomorrow’s medicine looks promising, but not guaranteed. Trends in chronic disease and organ scarring give drug developers a strong reason to dig deeper. More data on fibrosis reduction, especially for heart, lung, or kidney disease, could tip the drug from specialty therapy to front-line status. The compound’s structure holds a lot of appeal for medicinal chemists, with plenty of room to optimize absorption and target selectivity. Teams also keep probing its impact on cancer-related fibrosis, where tissue scarring helps tumors endure and spread. To keep progress going, the medical community leans on clear clinical data, careful postmarket observation, and collaboration between researchers worldwide. Increased attention to molecular mechanisms and patient outcomes could push tranilast into broader global use and stretch its impact even further in the fight against chronic inflammation and tissue damage.
Tranilast is not a household name for most people. At a family gathering, relatives toss around drug names like aspirin or insulin. Tranilast barely slips into the conversation, despite its history and wide-reaching effects. Yet it’s a medication that has changed the course for many with allergies, scars, and chronic illnesses.
Thirty years ago, Tranilast started out in Japan, prescribed to calm allergy symptoms—hay fever, asthma, and the itch of atopic dermatitis. I remember my neighbor using steroid creams for eczema and wrestling with the side effects. Tranilast gave people like her another option. It works by blocking the release of histamine and chemical signals that drive inflammation. For children running playgrounds despite spring allergies, or adults wrestling with red, swollen skin, the relief can feel like a weight off their shoulders.
Where Tranilast stands out comes after injuries or surgeries. Excessive scar tissue, known as keloids or hypertrophic scars, forms in some skin types regardless of how carefully cuts are managed. Nothing discourages like a raised scar along the arm or jaw. Tranilast, often in capsule or topical form, helps keep the scar-making cells in check. This means fewer visits to dermatology clinics for painful injections or laser sessions.
Inflammation doesn’t just bother skin. Over time, researchers noticed Tranilast’s effects in deeper tissues, especially organs at risk from chronic scarring. In the 2010s, Japanese doctors published reports of Tranilast slowing the loss of kidney function in people with diabetes. Diabetes throws a long shadow—once kidney tissues scar, people land in dialysis clinics or face transplant waiting lists. Tranilast suppresses key messengers like TGF-β, which fuel the body’s scarring response.
The stretch from allergies to kidney disease marks a remarkable shift. Scientists explored Tranilast in heart disease, lung fibrosis, even cancer. Most trials remain early-stage, data not strong enough for doctors worldwide to make it standard care. It’s clear, though, that Tranilast blocks signals driving the body’s bad habit of overreacting and laying down scar tissue where healing would do better.
Every medication brings a tradeoff. Tranilast can cause liver strain, digestive troubles, or mild rashes. Its approval sticks mostly to Japan and parts of Asia. Meanwhile, doctors in North America and Europe look for newer or better-studied options. The field of anti-scarring drugs moves slowly, though, because changing wound healing can easily tip from help to harm. Treating a lingering burn scar is one thing; interfering with the heart’s repair after a heart attack requires more caution.
More research can finally answer who benefits most from Tranilast. Clearer guidance, stronger studies, and monitoring will shape its future. Patients with thick scars, chronic allergies, or slow-burning organ inflammation have seen some hope from Tranilast, especially in places where other choices run thin. Better diagnosis of scarring conditions and fair access to prescription options lead the way for healthier living with fewer side effects and regrets.
Tranilast steps into the spotlight mainly as an anti-allergy medicine. It shows promise for conditions like asthma, keloids, and sometimes bladder issues. Like every medication, it brings a risk of unwanted effects. Some people who use tranilast report an upset stomach, nausea, or loose bowel movements. These gut issues stand out as the most widespread. Sometimes these pass as the body adjusts, but for others, discomfort sticks around and becomes a reason to call a doctor.
Liver health counts for a lot in anyone's daily well-being. Tranilast carries a track record for raising liver enzymes, found in the blood after a routine lab check. These changes don’t show up as pain, so they’re easy to miss unless a doctor looks for them. The risk goes up in people who already have a liver condition. Rare cases describe serious liver damage. It makes regular blood tests important, especially if someone plans to take the medicine long term.
The same careful watch should go for the kidneys. Reports have linked tranilast to changes in kidney function. Most folks with healthy kidneys never notice, but those with existing kidney concerns should get regular tests and stay hydrated. Ignoring kidney health can lead to fatigue, swelling, or more serious problems down the road.
Tranilast helps with allergies, but in rare moments, it can deliver its own allergic response. Itching, rashes, and redness can happen. Sometimes a severe allergy, such as swelling of the face or trouble breathing, needs quick medical help. Any medicine can trigger a reaction that falls outside the usual, and no one should brush off unexpected changes in skin condition or breathing.
A few people mention headaches, dizziness, or feeling sluggish. Rarely, an irregular heartbeat can begin after starting tranilast. Every person’s body deals with chemicals differently. Lifestyle plays a role—someone with high blood pressure, diabetes, or another chronic health issue should chat with a healthcare professional before starting a new drug. The same warning goes for anyone who takes several prescriptions, as tranilast can clash with other medicines.
Taking tranilast safely means more than popping a pill. Honest talks with a doctor about past health problems and any new symptoms should never feel like a burden. A pharmacist can answer questions about how different medicines work together. Reporting side effects to a healthcare provider or national monitoring agency isn’t just smart for the patient involved. Each report helps doctors, pharmacists, and future patients by highlighting new risks or patterns.
Careful steps before and during tranilast treatment help head off trouble. Blood tests for liver and kidney health, staying hydrated, and knowing the warning signs of allergic reactions make a difference. People can keep notes about new symptoms and share them at checkups. The story of tranilast, like so many medications, involves trade-offs. Understanding those risks lets each person and their doctor make the best call for a safer, healthier tomorrow.
Tranilast often enters conversations when people talk about managing allergic conditions or certain inflammatory diseases. Doctors may use it for asthma, keloids, and even some rare conditions like interstitial cystitis. The main idea behind using Tranilast centers on calming down the body’s histamine response, which makes it pretty useful for folks dealing with chronic inflammation or allergic flare-ups.
Tranilast usually comes as an oral capsule or tablet. Most prescriptions ask someone to take it two or three times each day, with a glass of water. The doctor decides the total daily dose, looking at severity of symptoms and any other ongoing treatments. From personal experience dealing with medication routines, sticking to a set schedule always helps—make it a ritual with breakfast and dinner, and forgetfulness drops. Skipping doses invites risk of symptoms flaring back up, which can lead to all sorts of complications down the line.
For swallowing capsules, I’ve always found that taking them with food reduces stomach irritation. Tranilast can sometimes cause mild digestive discomfort, including nausea or stomach cramps. Food not only eases this, but helps fold the pill-taking into daily life.
Doctors warn about drug interactions for a good reason. Tranilast interacts with some medications, such as warfarin, which can amplify its effects or lead to more side effects. Personally, I keep a written list with every medication and supplement I take. Sharing this with the doctor, again and again, avoids surprises. Blood tests may appear in the treatment plan, since Tranilast has shown rare cases of liver trouble. Marking those lab appointments on the calendar and not skipping them keeps everyone safe and informed.
Some people get drowsy or dizzy after taking Tranilast. Driving or operating machinery under those conditions rarely ends well. I always test out how a new medication feels on a quiet day at home, simply to stay out of trouble. If a rash or severe gastrointestinal symptoms show up, that’s a good reason to call the doctor’s office immediately. Sometimes, a reaction seems mild but turns severe quickly, so staying alert matters.
Doctors expect questions and appreciate honesty about how symptoms change. Transparency about missed doses, even if it feels embarrassing, helps tailor the next step. Regular check-ins, either through a call or a quick visit, keep everyone on the same page. Chronic illness never runs a straight road, and the treatment plan often shifts over time. Careful reporting of symptoms (improvement or new reactions) gives doctors what they need to rethink the schedule if necessary.
Building a routine around Tranilast, including reminders on the phone or sticky notes on the coffee maker, keeps things running smoothly. People who travel or lead busy lives might set up small weekly pill organizers. Tying the medication to existing habits, like brushing teeth or feeding a pet, cuts down on missed doses. Tracking side effects or flare-ups in a simple notebook can catch patterns early.
Tranilast isn’t a name you hear in a regular pharmacy conversation. Doctors have used this drug for allergic disorders, such as asthma and atopic dermatitis. In Japan and South Korea, Tranilast has made a mark for decades, and researchers are constantly looking at how it could help in other conditions: fibrosis, cancer, even rare genetic issues. A big part of its appeal comes from its ability to curb inflammation—blocking the release of histamine and other cytokines, which set off those lengthy allergic reactions that make life tough for so many.
If you try to pick up Tranilast at your local pharmacy, you’ll probably notice it's not on display. In many places, especially outside Japan and South Korea, you cannot buy Tranilast over the counter. You need a doctor’s order. That’s not just bureaucracy. This rule keeps people safe. Doctors want to monitor for side effects—liver strain, kidney issues—or pick up on allergy signs that might be easy to ignore.
People often underestimate the downsides of self-medicating. Tranilast isn’t a regular antihistamine like the ones lining store shelves. It shifts immune signals, which means anyone with liver disease, those taking other prescription medicines, or even folks using certain over-the-counter remedies, face real risks. I’ve seen how some patients come to harm assuming “allergy medicines” are harmless. Medical oversight really matters here.
The world is littered with stories of once-prescription drugs later sold without a visit to the doctor—think of ibuprofen, acid reflux meds, or steroids in some countries. The difference: Tranilast targets deeper immune functions, which sits closer to medicine’s trickier side than to its convenience.
Online forums whisper about getting Tranilast through unofficial channels. People desperate for relief or hoping for new treatments—especially those facing rare or chronic illnesses—often want to try whatever’s rumored to help. They search for it in the gray corners of the internet, risking counterfeit pills and dosing mistakes. Unchecked, this kind of desperation opens the door to a whole list of problems: drug interactions, low-quality products, unpredictable side effects, and a lack of real support.
Researchers across the globe keep testing Tranilast for new uses. If new trials find clear benefits—say, for types of cancer or genetic conditions—medical guidelines could shift, making safer access possible. Patient advocacy plays a role. People demanding newer, more effective treatments can push pharmaceutical companies and regulators to speed things up, run more studies, or even provide compassionate use programs. Doctors hearing from informed, vocal patients often drive this change from the ground up.
Those hoping for better access to Tranilast should talk openly with their healthcare team. If access remains tied to a prescription, that conversation gives doctors the power to protect, to advise, and sometimes to find safe alternatives or new trial opportunities that were not obvious before.
Tranilast’s restricted access holds a mirror to medicine’s tug-of-war between safety and convenience. While rules slow some people down, they exist to prevent harm and keep patient care grounded in evidence, not just hope or hype.
Tranilast came into the spotlight as an anti-allergy medication, especially for people living with asthma, atopic dermatitis, or keloids. Folks talk about its benefits, but there’s another side to the story worth hearing. Some people stand to lose more than they gain if Tranilast ends up in their medicine cupboard.
Anyone with a known allergy to Tranilast, its components, or similar medicines had best steer clear. Some allergic reactions don’t mess around — swelling, trouble breathing, bad rashes. That’s not just a warning on paper. Drug allergies can turn a regular afternoon into a trip to the emergency room. Taking it “just to see” isn’t worth it.
Livers and kidneys carry a heavy workload breaking down medicines and flushing out leftovers. Tranilast adds to that burden. Folks with poor liver or kidney function face the risk of dangerous buildup. I remember my neighbor, who lived with liver cirrhosis after years of hepatitis, saw his symptoms spiral just from trying a new pill. Extra stress on weak organs stacks up fast. Doctors flag people with chronic liver or kidney disease — the risks outweigh any benefit. Blood work isn’t just a formality here; it helps spot early warning signs before something serious happens.
Expecting mothers or women nursing babies have to weigh every medicine twice. Tranilast falls into a handful of drugs where research in pregnancy or for breastfeeding women just doesn’t reach a comfortable level. Animal studies give some clues, but people aren’t mice. Uncertainty about effects on developing babies lingers in the medical journals. Most obstetricians I know won’t prescribe it unless there’s no other option.
Tranilast wasn’t made with kids in mind. Most studies focus on grown adults. Prescribing it to children walks into uncharted territory, with unknowns on safety and how their smaller bodies handle the drug. Pediatricians tend to look for alternatives backed by clearer research on youngsters.
Tranilast doesn’t play nice with every medicine. Combining it with blood thinners, certain diabetes drugs, or other strong prescriptions sets the stage for weird interactions. For instance, warfarin and Tranilast can together mess up normal clotting, raising bleeding danger. Diabetes patients on insulin or oral meds might see sudden changes in blood sugar balance. Anyone juggling multiple prescriptions should talk with their pharmacist or doctor before adding Tranilast into the mix.
Open conversations with doctors make a world of difference. Bring a list of health problems and other medicines. Ask point blank about risks. Regular blood tests track liver and kidney health, letting tweaks happen before real trouble starts. Reading up from trusted sources like the FDA, academic papers, or major hospital websites chips away at confusion. Patients get better results when they feel comfortable pressing for answers and double-checking every new prescription.
Tranilast has a place in clinics, but it’s not for everyone. People with allergies, liver or kidney trouble, pregnant or breastfeeding women, and children—each face risks that weigh heavily against benefits. Talking it through with a health professional who knows the full story beats making choices alone.
| Names | |
| Preferred IUPAC name | N-(3,4-dimethoxycinnamoyl)anthranilic acid |
| Other names |
SB 252218 INN: Tranilast |
| Pronunciation | /ˈtrænɪlæst/ |
| Identifiers | |
| CAS Number | 53902-12-8 |
| 3D model (JSmol) | `3D Model (JSmol)` string for **Tranilast**: ``` CC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2C(=O)O ``` This is the **SMILES** string for Tranilast, which is commonly used for 3D modeling in JSmol. |
| Beilstein Reference | 373672 |
| ChEBI | CHEBI:9730 |
| ChEMBL | CHEMBL960 |
| ChemSpider | 18699 |
| DrugBank | DB07605 |
| ECHA InfoCard | ECHA InfoCard 100.089.137 |
| EC Number | EC 4.2.1.78 |
| Gmelin Reference | 676889 |
| KEGG | D01774 |
| MeSH | D014247 |
| PubChem CID | 5282230 |
| RTECS number | GV2321000 |
| UNII | YN2R8W0N14 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C18H17NO5 |
| Molar mass | 357.344 g/mol |
| Appearance | light yellow crystalline powder |
| Odor | Odorless |
| Density | 1.348 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 2.96 |
| Vapor pressure | 1.79E-10 mmHg |
| Acidity (pKa) | 3.99 |
| Basicity (pKb) | 5.48 |
| Magnetic susceptibility (χ) | -72.3e-6 cm^3/mol |
| Refractive index (nD) | 1.653 |
| Dipole moment | 4.26 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -489.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4367 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | D10AX04 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | hazard, prescription, oral use, adult use |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Lethal dose or concentration | LD50 (rat, oral): > 2,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Tranilast: "Tranilast LD50 (rat, oral): >2,000 mg/kg |
| NIOSH | DNW102J8DU |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Tranilast: "Not established |
| REL (Recommended) | 300 mg daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Tranilastol Oxantranilast |
